1 2	Network-based spreading of grey matter changes across different stages of psychosis
2 3 4 5 6	Sidhant Chopra ^{1,2,3} , Ashlea Segal ^{1,2} , Stuart Oldham ^{1,2} , Alexander Holmes ^{1,2} , Kristina Sabaroedin ^{1,2,12} , Edwina R. Orchard ^{1,2,4} , Shona M. Francey ^{5,6} , Brian O'Donoghue ^{5,6} , Vanessa Cropley ⁷ , Barnaby Nelson ^{5,6} , Jessica Graham ^{5,6} , Lara Baldwin ^{5,6} , Jeggan Tiego ^{1,2} , Hok Pan Yuen ^{5,6} , Kelly Allott ^{5,6} , Mario Alvarez-Jimenez ^{5,6} , Susy Harrigan ^{5,6,8} , Ben D. Fulcher ⁹ , Kevin
7 8	Aquino ^{9,10} , Christos Pantelis ^{7,13} , Stephen J Wood ^{5,6,11} , Mark Bellgrove ¹ , Patrick McGorry ^{5,6} , Alex Fornito ^{1,2}
9	
10	
11	
12	1. Turner Institute for Brain and Mental Health, School of Psychological Sciences, Monash
13	University, Clayton, Australia
14	2. Monash Biomedical Imaging, Monash University, Clayton, Australia
15	3. Department of Psychology, Yale University, New Haven, USA
16	4. Child Study Centre, Yale University, New Haven, USA
17	5. Orygen, Parkville, Australia
18	6. Centre for Youth Mental Health, The University of Melbourne, Melbourne, Australia
19	7. Melbourne Neuropsychiatry Centre, Department of Psychiatry, University of Melbourne
20	8. Centre for Mental Health, Melbourne School of Global and Population Health, The
21	University of Melbourne, Parkville, Australian
22	9. School of Physics, University of Sydney, New South Wales, Australia
23	10. Centre for Complex Systems, University of Sydney, New South Wales, Australia
24	11. School of Psychology, University of Birmingham, Edgbaston, UK
25 26	12. Departments of Radiology and Paediatrics, Hotchkiss Brain Institute and Alberta Children's Hospital Research Institute, University of Calgary, Calgary, AB, Canada
27	13. NorthWestern Mental Health, Royal Melbourne Hospital & Western Hospital Sunshine,
28	St Albans, Victoria, Australia
29	
30	
31 32	
33	
34	
35	
36	
37	
38	
39	
40	
41	Corresponding Author:
42	Sidhant Chopra (<u>sidhant.chopra@yale.edu</u>)
43	Yale University
44	Department of Psychology

45 Key points (max 100 words)

47 Question Are grey matter changes across the psychosis continuum constrained by brain48 network architecture and are certain regions epicentres of volume loss?

Findings Across four independent samples spanning different stages of psychotic illness, 51 grey matter alterations are strongly constrained by the underlying architecture of the brain's 52 axonal pathways and the hippocampus is consistently identified as a putative source from 53 which volume-loss may spread to connected regions.

Meaning White matter fibres may act as conduits for the spread of pathology across all 56 stages of psychotic illness and medial temporal regions play a critical role in the origins of 57 grey matter reductions.

- . 0

- .

76 Abstract (350 words)

77 Importance: Psychotic illness is associated with anatomically distributed grey matter reductions that 78 can worsen with illness progression, but the mechanisms underlying the specific spatial patterning of 79 these changes is unknown.

80

81 **Objective:** To test the hypothesis that brain network architecture constrains cross-sectional and 82 longitudinal grey matter alterations across different stages of psychotic illness and to identify whether 83 certain brain regions act as putative epicentres from which volume loss spreads.

84

85 Design, Settings, Participants: This study included 534 individuals from 4 cohorts, spanning early 86 and late stages of psychotic illness. Early-stage cohorts included patients with antipsychotic-naïve 87 first episode psychosis (N=59) and a group of medicated patients within 3 years of psychosis onset 88 (N=121). Late-stage cohorts comprised two independent samples of people with established 89 schizophrenia (N=136 in total). Each patient group had a corresponding matched control group 90 (N=218 in total). A further independent sample of healthy adults (N=346) was used to derive 91 representative structural and functional brain networks for modelling of network-based spreading 92 processes. We additionally examined longitudinal illness-related and antipsychotic-related grey matter 93 changes over 3 and 12 months using a triple-blind randomised placebo-control MRI study of the 94 antipsychotic-naïve patients. All data were collected between April 2008 and January 2020, and 95 analyses were performed between March 2021 and January 2023.

96

97 Main Outcomes and Measures: We used coordinated deformation models to predict the extent of 98 grey matter volume change in each of 332 parcellated areas by the volume changes observed in areas 99 to which they were structurally or functionally coupled. To identify putative epicentres of volume 100 loss, we used a network diffusion model to simulate the spread of pathology from different seed 101 regions. Correlations between predicted and empirical spatial patterns of grey matter volume 102 alterations were used to quantify model performance.

103

104 Results: In both early and late stages of illness, spatial patterns of cross-sectional volume differences 105 between patients and controls were more accurately predicted by coordinated deformation models 106 constrained by structural, rather than functional, network architecture (.46 < r < .57; p < .001). 107 The same model also robustly predicted longitudinal volume changes related to illness (r > 52; p < 1108 .001) and antipsychotic exposure (r > .50; p < .001). Diffusion modelling consistently identified, 109 across all four datasets, the anterior hippocampus as a putative epicentre of pathological spread in 110 psychosis (all p < .05). Epicentres of longitudinal grey matter loss were apparent posteriorly early 111 in the illness and shifted anteriorly to prefrontal cortex with illness progression.

112

Conclusion and Relevance: Our findings highlight a robust and central role for white matter fibres as conduits for the spread of pathology across different stages of psychotic illness, mirroring findings reported in neurodegenerative conditions. The structural connectome thus represents a fundamental constraint on brain changes in psychosis, regardless of whether these changes are caused by illness or medication. Moreover, the anterior hippocampus represents a putative epicentre of early brain pathology from which dysfunction may spread to affect connected areas.

- 120
- 121
- 122
- 123

124 Introduction

125 Psychotic disorders such as schizophrenia are characterised by anatomically distributed reductions in 126 grey-matter volume (GMV)¹⁻⁷, many of which show evidence of progression over time and across different stages of illness⁸⁻¹⁴. Meta- and mega-analyses indicate that some of the most robust cross-127 sectional GMV reductions are found in frontal, cingulate and temporal cortices, as well as medial 128 temporal lobe and thalamus^{3-7,15-17}, with longitudinal reductions identified in frontal, temporal and 129 parietal cortices^{9,11}. However, despite a large literature describing the location and nature of these 130 131 brain changes, the specific mechanisms that give rise to their characteristic spatial pattern remain 132 unknown.

133

134 The human brain is an intricate network of functionally specialised regions linked by a complex web of axonal fibres, referred to as a connectome¹⁸. These fibres enable the widespread coordination of 135 136 neuronal dynamics and the transport of trophic and other biological molecules throughout the brain. 137 They can also act as conduits for the spread of pathology, such that illness processes originating in 138 one area can propagate to affect distributed systems via multiple mechanisms^{19,20}. This principle has 139 been powerfully demonstrated in dementia, where GMV reductions in different neurodegenerative 140 conditions have been shown to spread through the brain in a way that is constrained by the underlying 141 architecture of the brain's white-matter pathways²¹⁻²⁴.

142

Recent work suggests that a network-based spreading process may also be involved in psychosis. Cross-sectional grey-matter reductions in patients correlate with increased fractional anisotropy in regionally adjacent white matter²⁵, are often correlated across spatially distributed regions²⁶⁻²⁸, and correspond with normative connectome organisation^{29,30}. In recent work, Shafiei, et al. ³¹ developed a coordinated-deformation model (CDM) in a sample of people with established schizophrenia that predicted the level of cross-sectional GMV reduction in an area based on the average reductions observed in other areas to which it was structurally connected.

150

151 Together, these findings support the hypothesis that the spatial patterning of GMV loss in psychotic 152 illness is constrained by connectome architecture. However, the few studies addressing this question 153 have been cross-sectional and only examined patients with chronic illness, precluding an opportunity 154 to track how coordinated grey-matter changes evolve through time and across illness stages. It thus 155 remains unclear whether longitudinal GMV changes are actually constrained by brain network 156 architecture, as would be expected for a network-based spreading process. Moreover, the reliance on 157 samples of patients taking antipsychotic medication makes it difficult to determine whether coupled 158 grey-matter changes are driven by treatments for the illness or the illness process itself.

159

160 Here, we used multiple cohorts spanning different stages of psychosis to comprehensively evaluate 161 network constraints on cross-sectional and longitudinal GMV changes. Specifically, we evaluated the 162 capacity of different CDM variants, constrained by distinct aspects of connectome structure or 163 function, to model cross-sectional GMV differences in two samples of patients at early illness stages 164 and two samples of patients at later stages, allowing for independent replication of our findings at 165 each stage. The early-stage samples comprised a group of antipsychotic-naïve first episode psychosis 166 patients and a group of medicated patients within 3 years of illness onset. The late-stage samples 167 comprised two independent samples of people with established schizophrenia. We additionally 168 leveraged longitudinal data acquired within the context of a longitudinal, randomised placebo-169 controlled study in the antipsychotic-naïve FEP group^{32,33} to evaluate the degree to which the CDMs 170 predicted longitudinal GMV changes attributable to either antipsychotic medication or the illness

171 process itself, as observed over 3- and 12-month intervals. We then used a network-based diffusion 172 model to simulate the dynamic progression of GMV loss from different seed areas to determine 173 whether specific brain regions act as putative sources or epicentres of network-based spread. This 174 approach thus allowed us to robustly investigate the degree to which brain network architecture

- 175
- constrains a diverse array of cross-sectional and longitudinal GMV pathology across different stages
- 176 of psychosis and to identify possible focal points of early brain volume loss.
- 177

178 Methods

179 **Sample characteristics**

180 This study used data from four independent datasets sampling different stages of the psychotic-illness continuum: the STAGES clinical trial^{13,33} (first episode psychosis; FEP), Human Connectome Project 181 Early Psychosis³⁴ (early psychosis; EP), BrainGluSchi³⁵ (schizophrenia; SCZ-BGS), and COBRE³⁶ 182 183 (schizophrenia; SCZ-COBRE). Hereafter, these cohorts will be referred to as FEP, EP, SCZ-BGS and 184 SCZ-COBRE, respectively. We also derived representative structural and functional connectomes 185 using a large independent healthy control sample. The final number of included subjects, 186 demographic and diagnostic characteristics are described in Table 1 and additional details about each 187 dataset are provided in the Supplement1A.

- 188
- 189
- 190

	First episode psychosis (FEP) N=86			Early psychosis (EP) N=178		Schizophrenia (SCZ-COBRE) N=138		Schizophrenia (SCZ-BGS) N=132		Independent healthy control N=356	
	Placebo	Antipsychotic	Matched control	Patient	Matched control	Patient	Matched control	Patient	Matched control	Independent healthy control	
N	B1=30; 3m=21; 12m=22	B1 =29; 3m = 20; 12m =14	Bl =27; 3m = 21; 12m =21	121	57	66	72	70	62	356	
Baseline age, years ± SD	18.8±2.7	19.5±2.9	21.9±1.9	23.3±3.9	23.4±3.9	38.0±14.1	35.9±11.7	36.6±13.4	38.22±12.4	23.7±5.4	
Baseline Females, N (%)	14 (46.6)	13 (44.8)	17 (62.9)	47 (38.9)	30 (35.0)	12 (18.8)	23 (31.9)	10 (14.2)	14 (22.6)	198 (55.6)	
Diagnosis, N											
Major depression w/ psychosis	7	5	-	5	-	0	-	0	-	-	
Schizophreniform disorder	5	5	-	8	-	0	-	0	-	-	
Psychotic disorder NOS	8	7	-	0	-	0	-	0	-	-	
Substance- induced psychotic disorder	4	2	-	0	-	0	-	0	-	-	
Delusional disorder	1	4	-	0	-	0	-	0	-	-	
Schizoaffective disorder				13	-	6	-	0	-	-	
Schizophrenia	5	5	-	61	-	60	-	70	-	-	
Bipolar Disorder w/ psychosis	0	0	-	25	-	0	-	0	-	-	
Missing diagnosis	0	1	-	0	-	0	-	0	-	-	
Illness Duration (Years)	<0.5	<0.5	-	1.8 (1.4)	-	16.0 (12.2)	-	18.2 (12.9)	-	-	

Symptom severity, scale; mean ± SD	Baseline BPRS Total 59.4 ±9.64	Baseline ; BPRS Total; - 55.8 ±10.10	PANSS Total; - 49.7±11.0	PANSS Total; - 58.4±13.6	PANSS; 60.7±16.9
Functional outcome, scale; mean ± SD	Baseline SOFAS; 52.9 ±14.0	Baseline SOFAS; - 51.7±10.6	GAF; 66.4± - 16.6	CGI; 3.7±0.6	CGI; 3.9± 0.8

191 Table 1 - Sample characteristics of included datasets.

Abbreviations: NOS = not otherwise specified; BPRS = Brief Psychiatric Rating Scale version 4; SOFAS =
Social and Occupational Functioning Assessment Scale; Bl = baseline, 3m = 3-months, 12m = 12months;
PANSS = Positive and Negative Syndrome Scale, GAF = Global Assessment of Functioning Scale (average of
the social and occupational rating items); CGI: The Clinical Global Impressions Scale.

- 196
- 197

198 Structural MRI processing

199 Acquisition parameters for structural MRI can be found in Supplement1B. Prior to processing, raw 200 T1w scans were visually examined for artefacts and then subjected to an automated quality control 201 procedure³⁷. In the FEP, EP, SCZ-BGS and SCZ-COBRE datasets, three, eight, six and four patient 202 scans did not pass image quality control, respectively, and were excluded due to artefacts (see 203 Supplement). The remaining scans were processed using the deformation-based morphometry (DBM) pipeline of the Computational Anatomy Toolbox (version r1113)³⁸ for the Statistical Parametric 204 Mapping 12³⁹ software running in MATLAB version 2019a (details in the Supplement1C). We used 205 206 DBM to quantify volume changes because it does not require tissue segmentation, requires less spatial 207 smoothing⁴⁰ than voxel-based morphometry (VBM) and to be comparable to previous work^{24,31}. 208 However, we replicated our primary findings using VBM (see Robustness analyses).

209

210 Quantifying cross-sectional and longitudinal grey matter changes in patients

To map spatial patterns of group-level cross-sectional and longitudinal volume change, we used a robust marginal model implemented in the Sandwich Estimator Toolbox⁴¹, which combines ordinary least squares estimates of parameters of interest with estimates of variance/covariance based on a robust sandwich estimator, thus accounting for within-subject correlations in longitudinal studies. This method is asymptotically robust to misspecification of the covariance model and does not depend on the assumptions of common longitudinal variance structure across the whole brain. All contrasts were adjusted for age, sex, and handedness, with site additionally included for the EP dataset.

218

219 We conducted cross-sectional contrasts in each of the four patient datasets to capture cross-sectional 220 GMV differences between patients and controls (Fig1A). Longitudinal GMV changes were mapped in 221 the FEP dataset (Fig1A) to isolate: (1) illness-related change over time, by comparing GMV changes 222 overt time in the placebo group to matched healthy controls; and (2) antipsychotic-related changes 223 over time, which compared GMV changes in the medication group to both the placebo group and 224 matched healthy controls (see also¹³). Longitudinal contrasts were assessed from baseline to 3 months 225 and baseline to 12 months, with a linear contrast being used for the latter. Contrasts were specified 226 such that positive values in the resulting voxel-wise t-statistic maps indicate lower volume in patients 227 compared to controls at cross-sectional contrast, and a greater longitudinal GMV decline in patients 228 compared to controls in the longitudinal contrasts. The t-statistics were converted to z-scores, and we 229 applied the CDM to unthresholded z-maps encoding regional GMV changes, as we are interested in 230 capturing the spatial patterning of GMV differences across the entire brain, not just the changes which 231 survive a statistical threshold. Renderings of the unthresholded t-maps can be found in Fig1A-C and 232 Fig2A-B. FDR-corrected and uncorrected voxel-level t-statistic maps for each contrast are provided in 233 the Supplements1F-1G.

234

235 Brain Parcellation

To relate grey-matter alterations to connectome architecture, we parcellated the brain into 300 discrete cortical regions of approximately equal size⁴², in addition to 32 subcortical areas⁴³, using previously validated atlases. The volume change for each region was estimated as the mean *z*-statistic of all voxels corresponding to that region. The regions comprise the nodes of a network, which can then be directly related to measures of inter-regional SC and FC.

241


242 Healthy reference connectomes

We derived a group-level healthy structural connectome from diffusion-weighted imaging (DWI) data from an independent sample of 356 adults (Fig1B; Table 1), which served as a reference connectome for computational modelling. Acquisition parameters and detailed overview of DWI processing and optimisation can be found in Supplement1D. This procedure resulted in a single 332 × 332 weighted group-average SC matrix.

248

We also derived a group-level healthy functional connectome from resting-state fMRI data acquired in the same independent sample of adults (Fig1B). Acquisition parameters for functional MRI and detailed information on fMRI processing can be found in Supplement1E. Given ongoing controversy around the application of global signal regression^{44,45}, we evaluated how this step affected our findings (see *Robustness analyses*). After processing and denoising, we computed a whole-brain 332×332 FC matrix for each subject using pair-wise Pearson correlations between the timeseries of each of the 332 regions and finally took a mean FC matrix across the sample.







258 Fig1. - Analysis workflow for the Coordinated Deformation Model. (A) We derived voxel-wise GMV 259 estimates using Deformation-based morphometry (DBM). Five separate contrasts were specified using a robust 260 marginal model to infer baseline GMV differences and longitudinal GMV changes associated with illness and 261 antipsychotic medication at 3 months and 12 months. (B) The contrast statistics were mapped to a brain 262 parcellation comprising 332 regions, and diffusion and functional MRI data from an independent healthy sample 263 were used to generate sample-averaged functional coupling (FC) and structural connectivity (SC) matrices. 264 These matrices were used to model average volume changes in structurally connected neighbours. Under the 265 CDM, the predicted deformation of a node, \hat{d}_i , is modelled as a weighted sum of the deformation values

266 observed its structurally connected neighbours (shown as light blue nodes in the example graphs). The weights 267 are given by the adjacency matrix, A_{ij} . Three different matrices were used, yielding three CDM variants; (1) A 268 model denoted as CDM_{SC}, in which $A_{ii} = 1$ if two regions share a connection and $A_{ii} = 0$ otherwise; (2) a 269 model denoted as CDM_{SCW} in which the elements of A_{ij} correspond precisely to the weighted SC matrix, such 270 that the contribution of each neighbour is weighted by the strength of its structural connectivity to the index 271 node; and (3) a model denoted CDM_{FCw} , in which the elements of A_{ii} correspond precisely to the weighted FC 272 matrix, such that the contribution of each neighbour is weighted by its FC with the index node. (C) Model 273 performance was evaluated using the Pearson correlation between regional estimates of observed and predicted 274 GMV differences. (D) We also compared model performance to three benchmark null models accounting for 275 spatial autocorrelations in the deformation maps (Null_{smash} and Null_{spin}) and basic topological properties of the 276 connectome (Null_{rewire}; see CDM evaluation).

278 Coordinated Deformation Model (CDM) – Network Constraints

We evaluated network constraints on cross-sectional and longitudinal GMV changes using the CDM
 introduced by Shafiei, et al. ³¹. The model is given by

 $\hat{d}_i = \frac{1}{N_i} \sum_{j=1, j \neq i}^{N_i} A_{ij} d_j ,$

282 283

where \hat{d}_i is the predicted GMV change in node *i*, N_i is the number of structurally connected neighbours of *i*, d_j is the deformation observed in the *j*-th neighbour of node *i*, and A_{ij} defines the connectivity between nodes *i* and *j*.

287

Three different matrices were substituted for A_{ij} , yielding three variants of the CDM (Fig1B). For the first model, denoted CDM_{SC}, A_{ij} =1 if nodes *i* and *j* are connected in the group-average SC matrix and zero otherwise. Therefore, all *j* structurally connected neighbours make an equal contribution to predicting the extent of deformation observed in node *i*.

292

For the second and third models, denoted CDM_{SCw} and CDM_{FCw} , A_{ij} corresponded to the weighted SC or FC matrices, respectively. Therefore, under these models, the contributions of node *i*'s neighbours were weighted by either inter-regional SC (CDM_{SCw}) or FC (CDM_{FCw}) estimates, such that neighbours of node *i* with a more strongly weighted connection made a stronger contribution to predicting node *i*'s volume change (Fig1B). In all models, only edges that had a corresponding structural connection were included and SC and FC edge weights were taken from the healthy reference connectome, unless otherwise specified.

300

301 CDM evaluation

302 Model performance was evaluated using the product-moment correlation (r) between region-wise 303 estimates of observed and predicted deformation (Fig1C). We also compared the performance of the 304 CDM_{SC}, CDM_{SCw} and CDM_{FCw} models to three benchmark null models. The first (Fig1D; Null_{smash}) 305 and second (Fig1D; Null_{spin}) null models evaluated whether the observed findings were specific to the 306 empirically observed pattern of grey-matter deformations or were a generic property of the intrinsic 307 spatial correlation structure of the deformation maps. The third null model (Fig1D; Null_{rewire}) tests the 308 hypothesis that any network-based prediction of local grey-matter change is specific to the actual 309 topology of the connectome itself and cannot be explained by basic network properties, such as 310 regional variations in node degree or the spatial dependence of inter-regional connectivity⁴⁶. Further 311 details about benchmark null models can be found in the Supplement1H.

312

313 Network Diffusion Model (NDM) – Epicentre Identification

314 The CDM evaluates the degree to which spatial patterns of GMV change are shaped by connectome 315 properties. A close coupling between GMV change and network architecture implies that volume loss 316 spreads through the connectome, but the CDM offers limited insight into the dynamics of the 317 spreading process, nor is it able to identify regions from which the spreading may initiate. We 318 therefore used a NDM to directly test whether GMV loss spreads through the brain via a process of 319 diffusion and whether certain brain regions act as sources, or epicentres, of pathological spread 320 through the brain (Fig4)⁴⁷. The NDM simulates the dynamic spread of pathology between the nodes 321 of a weighted network via a process of diffusion (Fig4A), defined as

- 322
- 323 324

 $f(t) = e^{-\alpha H t} f_0 ,$

325 where t is the model diffusion time, which has arbitrary units (a.u.), and f(t) is a vector 326 characterizing the amount of diffusion in each region at time t. The strength of the diffusion process 327 is controlled by a constant (α) and H is the Laplacian of the weighted SC matrix. f_0 represents the 328 initial distribution of pathology. We repeatedly initialized the model using each of the 332 regions as 329 the starting seed, such that the initial state was set to 1 for the seed region, and 0 for all other regions. 330 At each initialization, using a constant of $\alpha = 1$, the NDM was used to estimate the diffusion at all 331 other regions at time t = 0 to 50. In this way, we were able to determine whether a diffusion process 332 seeded from each region resulted in a spatial distribution of volume loss that matched the empirically 333 observed patterns. Further information about the NDM can be found in the Supplement11.

334

335 NDM evaluation

Consistent with prior work 47,48, model performance was evaluated as the Pearson correlation between 336 337 the predicted diffusion and observed volume abnormalities at each time step and for each seed, with 338 the maximum correlation (Fig4A; r_{max}) across all time steps being retained. The observed regional t-339 statistics were rescaled to a more interpretable non-negative quantity via a log-transformation, 340 yielding values in the range $[0,1]^{47.49}$. The seed region was excluded when correlating predicted and 341 observed volume abnormalities to ensure that our analysis was not influenced by large volume 342 abnormalities in the seeds. The performance of the NDM in capturing the empirical maps of GMV 343 change was compared to its performance in capturing surrogate maps generated using the Nullsmash and 344 Null_{rewire} benchmark models (Fig4A). The Null_{spin} benchmark was not used to evaluate the NDM as it 345 does not include subcortical regions. Further details about benchmark null models used to evaluate the 346 NDM can be found in the Supplement11.

347

To aid comparison with previous research³¹, we also implemented a data-driven approach to epicentre identification that defines epicentres as regions with high volume loss that are also connected to other regions with high volume loss (FigS2; see Supplement1J for details). The spatial locations of epicentres identified by this approach closely aligned with the results of the NDM epicentre analysis.

352


353 Results

354 Structural connectivity shapes cross-sectional grey matter differences across illness stages

We first evaluated the performance of the three CDMs in capturing cross-sectional differences in regional GMV. In all datasets, the CDM_{SCw} model yielded more accurate predictions of crosssectional empirical GMV case-control differences (.46 < r < .57; Fig2E-H) when compared with

the CDM_{SC} and CDM_{FCw} models (*all* r < .35; Fig2E-H). For all data sets, the performance of the CDM_{SCw} was also significantly better than all three benchmark models (all p < 0.01). The CDM_{SC} and CDM_{FCw} generally did not surpass the performance of the benchmark models.

- 361
- 362



363

364 Fig2. – Baseline and longitudinal illness-related GMV changes are constrained by connectome 365 anatomy. (A-D) The contrast statistics for four cross-sectional contrasts mapped to a brain 366 parcellation comprising 332 regions. (E-H) Performance of the equally weighted (CDM_{sc}), structural 367 connectivity-weighted (CDM_{SCw}), and functional coupling-weighted (CDM_{FCw}) models relative to the 368 Null_{smash}, Null_{spin}, and Null_{rewire} benchmarks. Black circles indicate the observed rank correlations 369 between predicted and actual regional deformation values for each model at each timepoint, with red 370 borders indicating statistical significance. Note that the observed value used for comparison against 371 the Null_{spin} models is different because the subcortex was excluded. (I-L) Scatterplots of the 372 association between observed and predicted regional volume deformation values for the best 373 performing CDM_{SCw} model at each timepoint.

374

375 Structural connectivity shapes longitudinal GMV changes

376 Having robustly demonstrated that cross-sectional grey matter differences at different illness stages 377 are related to connectome structure, we next tested the implicit assumption of the CDM—that 378 longitudinal GMV changes spread across axonal pathways—by considering longitudinal illness-379 related and medication-related changes in the FEP sample.


380

381 Predictions of the CDM_{SCw} model for illness-related grey matter changes at 3 and 12 months were 382 correlated with empirical changes at r = .58 (Fig3E) and r = .52 (Fig3F), respectively, and both 383 were significantly better than all three benchmark models (all p < .001). By comparison, correlations

for the CDM_{SC} and CDM_{FCw} did not exceed r = .38 and only showed significantly better performance compared to the Null_{smash} and the Null_{spin} at 3 months, but not connectome benchmarks (all p > 0.05; Fig2E – F).

387

388 Predictions of the CDM_{SCw} model for antipsychotic-related grey-matter changes were correlated with 389 the empirical maps at r = .51 (Fig3E) for 3 months and r = .25 (Fig3F) for 12 months. This 390 association was statistically significant when compared to all three null models (all p < 0.01; Fig3C-391 D). Associations at 3 months and 12 months were smaller for the CDM_{SC} (r = .34 and r = .24, 392 respectively) and CDM_{FCw} models (r = .38 and r = .31, respectively). At 3 months, the CDM_{SC} and 393 CDM_{FCw} models only showed significantly better performance than the Null_{smash} and Null_{soin} (p < 1394 .01) benchmarks. At 12 months, the CDM_{SC} model showed significantly better performance than the 395 Null_{smash} and Null_{rewire} benchmarks and the CDM_{SC} model showed significantly better performance 396 than the Null_{smash} and Null_{spin} benchmarks (p < .05). Thus, connectome structure represents a generic 397 constraint on both illness-related and medication-related longitudinal GMV changes in psychosis. 398



399

400 Fig3 – Longitudinal illness-related and antipsychotic-related GMV changes are constrained by 401 connectome anatomy. (A-D) The contrast statistics for illness-related and antipsychotic-related 402 contrasts mapped to a brain parcellation comprising 332 regions. (E-H) Performance of the equally 403 weighted (CDM_{SC}), structural connectivity-weighted (CDM_{SCw}) and functional coupling-weighted 404 (CDM_{FCw}) models relative to the Null_{smash}, Null_{spin}, and Null_{rewire} benchmarks. Black circles indicate 405 the observed rank correlations between predicted and actual regional deformation values for each 406 model at each timepoint, with red borders indicating statistical significance. Note that the observed 407 value used for comparison against the Null_{spin} models is different because the subcortex was excluded. 408 (I-L) Scatterplots of the association between observed and predicted regional deformation values for 409 the best performing CDM_{SCw} model at each timepoint.

410

411 Epicentres of grey matter volume loss

412 We next used the NDM to simulate the dynamic spread of GMV loss from each individual brain 413 region. Results using the Null_{smash} benchmark are presented below (Fig4C-J) and results using the 414 Nullrewire benchmark are presented in the Supplement (FigS4). Across all cross-sectional comparisons, 415 medial temporal lobe regions emerged as statistically significant epicentres (Fig4C-F). In particular, 416 the anterior hippocampus was consistently implicated across all datasets (p < 0.05), surviving 417 multiple comparison correction ($p_{FWE} < 0.05$) in the two schizophrenia samples. In the FEP dataset, 418 additional epicentres were identified in bilateral occipital and temporal cortex, as well as 419 hippocampus, amygdala, and posterior thalamic regions (Fig4C). In the EP dataset, additional 420 epicentres were identified in temporal and posterior cingulate cortex, (Fig4D). In both schizophrenia 421 samples, additional epicentres were identified in temporal cortex, amygdala, and posterior thalamic 422 regions (Fig4E-F). Consistent results were obtained using the Null_{rewire} benchmark (FigS4).

423

424 In the FEP sample, epicentres of longitudinal illness-related loss were identified in medial frontal 425 regions at 3 months and progressed to include much of the frontal cortex, as well as striatal and 426 thalamic regions, by 12 months (Fig4G-H). Comparison with the connectome-based null benchmarks 427 were more conservative, but also implicated prefrontal regions (FigS4).

428

429 Epicentres of longitudinal antipsychotic-related GMV loss in FEP were identified in sensorimotor,


430 cingulate and insula cortices, as well as thalamic and amygdala regions at 3 months, with the same

431 cortical epicentres also identified at 12 months (Fig4I-J). These results were largely consistent when

432 using the Null_{rewire} models (FigS4). Scatter plots of observed and predicted volume abnormalities for

433 all contrasts are provided in the Supplement (FigS3).





p < 0.05 $p_{FWE} < 0.05$

Fig4 - Regional epicentres of grey matter loss. (A) Epicentres were defined as potential sources of pathological volume loss from which GMV reductions spread (Blue) to affect structurally connected areas. To identify such regions, we simulated a spreading process using a Network Diffusion Model (NDM), (B) using each of the 332 parcellated regions as a seed, we retained the maximum correlation between the simulated and observed GMV abnormalities (r_{max}) . For each contrast, we then compared r_{max} values for each region to distribution of r_{max} values from two benchmark null models accounting for spatial autocorrelations in the deformation maps (Null_{smash}) and basic topological properties of the connectome (see Model evaluation (NDM)). Regional epicentres with significantly greater r_{max} than a spatially constrained null model (Orange = p < 0.05; Red = $p_{FWE} < 0.05$) are shown for cross-sectional (C-F) and longitudinal (G-J) effects. Results using Null_{rewire} benchmark models, and scatter plots of observed and predicted volume abnormalities are provided in Supplement (FigS3).

458 Robustness analyses

459 The magnitude and pattern of results remained consistent with our original findings after only 460 considering individuals diagnosed with schizophrenia or schizophreniform disorder, indicating that 461 diagnostic heterogeneity of the FEP and EP samples did not substantially impact our findings (FigS6). 462

To ensure that the wide-spread changes in white-matter integrity often reported in patients⁵⁰⁻⁵³ did not affect model estimates of the network-based spread of pathology, we replicated our findings using structural and functional connectomes derived from the FEP patient sample rather than the independent healthy control sample (FigS7). We also replicated the results using a representative structural connectome derived from the healthy control sample in the FEP study (FigS8).

468

469 Finally, our findings were consistent when using VBM instead of DBM (FigS9), and when applying
470 global signal regression (GSR) on subject-level FC matrices before computing the group average FC
471 matrix (FigS10).

472 Discussion

473 The mechanisms driving spatially patterned grey matter volume (GMV) changes in psychotic illness 474 have thus far been unclear. We have used a simple coordinated deformation model (CDM) to confirm 475 that, across both early and later stages of illness, cross-sectional GMV changes are shaped by the 476 topology and strength of structural, but not functional, connectivity between brain regions. We further 477 found that both illness-related and antipsychotic-related longitudinal changes are constrained by 478 structural connectivity, indicating that the temporal evolution of brain changes in the illness is also 479 constrained by the brain's axonal pathways. Moreover, using a network diffusion model (NDM) to 480 simulate the spread of pathology from different brain regions, we identified the anterior hippocampus 481 as a putative epicentre of volume loss across all illness stages and further showed a dynamic 482 progression of epicentres of dynamic grey matter loss from posterior to anterior areas, suggesting that 483 the pathological burden within temporal and prefrontal systems increases as the illness progresses.

484

485 Structural connectivity constrains GMV changes in psychotic illness

486 The strength and topology of the structural connectome shaped the spatial pattern of volume 487 abnormalities across both early and late stages of illness. Our findings in established schizophrenia 488 align with previous research using the CDM to show that structural connectivity constrains the spatial 489 patterning of cross-sectional GMV differences in people with established schizophrenia³¹. This earlier 490 result was observed using the CDM_{SC} model considered here. In our analysis, we found that the 491 strength of structural connectivity between regions modulates coupled GMV differences within 492 structurally connected neighbourhoods, given that the CDM_{SCw} showed clearly superior performance 493 to the CDM_{SC} and CDM_{FCw} models in all datasets. This result indicates that GMV differences are 494 more tightly coupled between areas with high structural connectivity. Critically, our findings show 495 that network constraints on cross-sectional GMV differences cannot be explained by antipsychotic 496 medication, as our FEP sample was antipsychotic-naïve at the baseline scan. Moving beyond cross-497 sectional differences, our longitudinal analysis further demonstrates that both illness-related and 498 antipsychotic-related changes in GMV are constrained by connectome architecture.

499

500 These results are in line with a spreading process in which pathology propagates across axonal 501 connections. The precise mechanisms driving this process remain unclear. While there is limited 502 evidence for visible deposits of aggregated pathological proteins in psychotic illness, more subtle 503 changes in protein homeostasis⁵⁴ may occur in subsets of patients and spread to synaptically

504 connected distant brain regions⁵⁵. Alternatively, and given the commonly reported finding of 505 functional brain alterations in psychotic disorders, dysfunction of one region may trigger abnormal 506 activity in connected sites which, over time, may trigger structural changes as a result of aberrant 507 neurotransmission or a loss of trophic support²⁰. This process may be exacerbated by a breakdown of 508 white-matter fibre integrity, which may further disrupt the inter-regional transport of trophic factors. 509 Accordingly, widespread but subtle alterations in white matter have been repeatedly demonstrated in psychosis populations⁵⁶, are anticorrelated with cortical thickness²⁵, and may predate the transition to 510 psychosis in high-risk samples^{50,51}. Although our analyses suggest that using a structural connectome 511 512 derived from a patient sample did not change the overall pattern of our findings, further work may 513 investigate how coordinated GMV changes interact with white-matter pathology in patients.

514

An alternative explanation for our findings is that regions sharing a strong anatomical connection have a more similar molecular and cytoarchitectonic profile, resulting in a shared vulnerability to illness- or treatment-related changes⁵⁷⁻⁶⁰. Future research should examine associations between the strength of structural connectivity and shared molecular features such as receptor profiles, gene expression, and synaptic density in patient populations.

521 The medial temporal lobe as an epicentre of grey matter differences in psychosis

522

520

523 Our NDM analysis indicated that the medial temporal lobe, and the anterior hippocampus in 524 particular, is a putative source of GMV loss in psychosis. The hippocampus has repeatedly been 525 implicated in the pathogenesis of psychosis. It has been linked to early neurodevelopmental 526 aberrations⁶¹⁻⁶³ and often shows lower levels of mRNA and protein markers of synaptic and dendritic function post-mortem^{64,65}. Recent *in vivo* PET imaging studies have also identified a loss of synaptic 527 528 vesicle proteins^{66,67}. Multiple animal models and human studies have indicated that a primary 529 dysfunction occurring within the hippocampus^{68,69}, such as a loss of pyramidal cell inhibition, results in downstream brain abnormalities including disinhibition of striatal dopamine release^{70,71} and 530 aberrant corticostriatothalamic functioning⁷². Other evidence suggests that dysregulation of glutamate 531 532 neurotransmission beginning in the CA1 region^{73,74} initiates the transition to psychotic illness and 533 eventuates in an atrophic process in which neuropil and interneurons are reduced in other medial 534 temporal and structurally connected regions.

535

536 537

Regional epicentres of longitudinal grey matter change dynamically evolve with illness progression

538 While the hippocampus was robustly implicated as a putative epicentre for cross-sectional GMV 539 differences at different illness stages, our analysis of longitudinal changes in the FEP group identified 540 putative epicentres in striatal and prefrontal areas. This contrasts the largely posterior focus of cortical 541 epicentres for baseline GMV differences in this group, suggesting that the most pronounced 542 longitudinal GMV changes occurring early in the illness affect the prefrontal cortex, which aligns 543 with the greater involvement of striatal and prefrontal areas at the 12 compared to 3-month follow-up. 544 These findings also accord with longitudinal studies in early-onset schizophrenia demonstrating a dynamic wave of volume contraction progressing from posterior to anterior regions,^{75,76} and other 545 evidence of pronounced prefrontal GMV reductions in the earliest stages of illness^{8,77-83}, which may 546 reflect an exaggeration of normal neurodevelopmental processes^{84,85}. Notably, these regional 547 548 epicentres of illness-related GMV loss were distinct from epicentres of antipsychotic-related GMV 549 loss, which were identified in somatosensory, motor, and posterior cingulate regions.

550

551 Limitations and conclusions

552 Our findings depend on group-level summary metrics of brain volume and may not be representative of volume changes at the individual patient level, which can show substantial heterogeneity⁸⁶⁻⁸⁸. 553 554 Subsequent work could look at whether using individual-level measures of brain volume and 555 connectivity can improve model predictions. Moreover, given the complexity and practical challenges 556 of conducting a prospective triple-blind randomised control MRI study in antipsychotic-naïve patients, the sample size of the longitudinal FEP sample is small (see also^{89,90} for a discussion of the 557 558 representativeness of this sample). Replication of our longitudinal analysis in larger samples is thus 559 warranted.

560

In summary, we identify a robust and central role for axonal connectivity as a conduit for the spread of pathology across early and late stages of psychotic illness, mirroring findings reported in neurodegenerative conditions. Our findings also align with animal models to suggest that medial temporal regions may play a critical role in the origins of brain dysfunction and indicate that the structural connectome represents a fundamental constraint on brain changes in psychosis, regardless of whether they are caused by illness or medication.

- 567
- 568
- 569
- 570
- 571
- 572
- 573
- 574
- 575
- 576
- 577
- 578
- 579
- 580
- 581
- 582

583 Disclosures/Conflict of Interest

584 SF, KA, MAJ and AF reported receiving grants from the Australian National Health & Medical 585 Research Council (NHMRC) and Australian Research Council (ARC) during the conduct of the 586 study. CP reported receiving grants from the Australian NHMRC and from the Lundbeck Foundation 587 and personal fees from Lundbeck Australia Pty Ltd Advisory Board for talks presented at educational 588 meetings organized by Lundbeck. PM reported receiving grants from the Australian NHMRC, the 589 Colonial Foundation, the National Alliance for Research on Schizophrenia and Depression, the 590 Stanley Foundation, the National Institutes of Health, Wellcome Trust, the Australian and Victorian 591 governments, and Janssen-Cilag (unrestricted investigator-initiated grant) during the conduct of the 592 study; past unrestricted grant funding from Janssen-Cilag, AstraZeneca, Eli Lilly, Novartis, and 593 Pfizer; honoraria for consultancy and teaching from Janssen-Cilag, Eli Lilly, Pfizer, AstraZeneca, 594 Roche, Bristol Myers Squibb, and Lundbeck. BN was supported by an NHMRC Senior Research 595 Fellowship (1137687) and a University of Melbourne Dame Kate Campbell Fellowship. This work 596 was supported by the computational infrastructure provided by the MASSIVE HPC facility 597 (www.massive.org.au).

598

500		Defermine
599 600		References
600 601	1	Cur D. E. Turretelay, D. L. Dillion, W. D. & Cur, D. C. Deduced Crew Metter Volume
601 602	1	Gur, R. E., Turetsky, B. I., Bilker, W. B. & Gur, R. C. Reduced Gray Matter Volume
602 603		in Schizophrenia. Archives of General Psychiatry 56, 905-911, doi:10.1001/archpsyc.56.10.905 (1999).
603 604	2	Haijma, S. V. <i>et al.</i> Brain Volumes in Schizophrenia: A Meta-Analysis in Over 18
605	2	000 Subjects. <i>Schizophrenia Bulletin</i> 39 , 1129-1138, doi:10.1093/schbul/sbs118
606		(2013).
607	3	Steen, R. G., Mull, C., Mcclure, R., Hamer, R. M. & Lieberman, J. A. Brain volume
608	5	in first-episode schizophrenia. British Journal of Psychiatry 188, 510-518,
609		doi:10.1192/bjp.188.6.510 (2006).
610	4	van Erp, T. G. M. <i>et al.</i> Cortical Brain Abnormalities in 4474 Individuals With
611	•	Schizophrenia and 5098 Control Subjects via the Enhancing Neuro Imaging Genetics
612		Through Meta Analysis (ENIGMA) Consortium. <i>Biological Psychiatry</i> 84, 644-654,
613		doi:10.1016/j.biopsych.2018.04.023 (2018).
614	5	van Erp, T. G. M. et al. Subcortical brain volume abnormalities in 2028 individuals
615		with schizophrenia and 2540 healthy controls via the ENIGMA consortium.
616		Molecular Psychiatry 21, 547-553, doi:10.1038/mp.2015.63 (2016).
617	6	Gupta, C. N. et al. Patterns of Gray Matter Abnormalities in Schizophrenia Based on
618		an International Mega-analysis. Schizophrenia Bulletin 41, 1133-1142,
619		doi:10.1093/schbul/sbu177 (2015).
620	7	Vieira, S. et al. Neuroanatomical abnormalities in first-episode psychosis across
621		independent samples: a multi-centre mega-analysis. Psychological Medicine 51, 340-
622	0	350, doi:10.1017/s0033291719003568 (2021).
623	8	Pantelis, C. <i>et al.</i> Neuroanatomical abnormalities before and after onset of psychosis:
624		a cross-sectional and longitudinal MRI comparison. <i>The Lancet</i> 361 , 281-288,
625 626	9	doi:10.1016/S0140-6736(03)12323-9 (2003). Vita, A., De Peri, L., Deste, G. & Sacchetti, E. Progressive loss of cortical gray matter
620 627	9	in schizophrenia: a meta-analysis and meta-regression of longitudinal MRI studies.
628		<i>Translational Psychiatry</i> 2 , e190-e190, doi:10.1038/tp.2012.116 (2012).
629	10	Akudjedu, T. N. <i>et al.</i> Progression of neuroanatomical abnormalities after first-
630	10	episode of psychosis: A 3-year longitudinal sMRI study. <i>Journal of Psychiatric</i>
631		<i>Research</i> 130 , 137-151, doi:10.1016/j.jpsychires.2020.07.034 (2020).
632	11	Olabi, B. <i>et al.</i> Are there progressive brain changes in schizophrenia? A meta-analysis
633		of structural magnetic resonance imaging studies. <i>Biological Psychiatry</i> 70 , 88-96,
634		doi:10.1016/j.biopsych.2011.01.032 (2011).
635	12	Andreasen, N. C. et al. Progressive Brain Change in Schizophrenia: A Prospective
636		Longitudinal Study of First-Episode Schizophrenia. Biological psychiatry 70, 672-
637		679, doi:10.1016/j.biopsych.2011.05.017 (2011).
638	13	Chopra, S. et al. Differentiating the Effect of Medication and Illness on Brain Volume
639		Reductions in First-Episode Psychosis: A Longitudinal, Randomized, Triple-blind,
640		Placebo-controlled MRI study. medRxiv (2020).
641	14	Liloia, D. et al. Updating and characterizing neuroanatomical markers in high-risk
642		subjects, recently diagnosed and chronic patients with schizophrenia: A revised
643		coordinate-based meta-analysis. <i>Neuroscience & Biobehavioral Reviews</i> 123 , 83-103
644	1.7	(2021).
645	15	Bora, E. <i>et al.</i> Neuroanatomical abnormalities in schizophrenia: A multimodal
646		voxelwise meta-analysis and meta-regression analysis. <i>Schizophrenia Research</i> 127 ,
647		46-57, doi:10.1016/j.schres.2010.12.020 (2011).

(10	16	
648	16	Fornito, A., Yücel, M., Patti, J., Wood, S. J. & Pantelis, C. Mapping grey matter
649		reductions in schizophrenia: An anatomical likelihood estimation analysis of voxel-
650		based morphometry studies. <i>Schizophrenia Research</i> 108 , 104-113,
651	17	doi:10.1016/j.schres.2008.12.011 (2009).
652	17	Del Re, E. C. et al. Anterior-posterior axis of hippocampal subfields across
653		psychoses: A B-SNIP study. Biomarkers in Neuropsychiatry 5, 100037,
654		doi: <u>https://doi.org/10.1016/j.bionps.2021.100037</u> (2021).
655	18	Sporns, O., Tononi, G. & Kötter, R. The Human Null _{rewire} : A Structural Description of
656		the Human Brain. PLOS Computational Biology 1, e42,
657		doi:10.1371/journal.pcbi.0010042 (2005).
658	19	Raj, A. & Powell, F. Models of Network Spread and Network Degeneration in Brain
659		Disorders. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging 3, 788-
660		797, doi:10.1016/j.bpsc.2018.07.012 (2018).
661	20	Fornito, A., Zalesky, A. & Breakspear, M. The connectomics of brain disorders.
662		doi:10.1038/nrn3901 (2015).
663	21	Seeley, W. W., Crawford, R. K., Zhou, J., Miller, B. L. & Greicius, M. D.
664		Neurodegenerative diseases target large-scale human brain networks. Neuron 62, 42-
665		52 (2009).
666	22	Zhou, J., Gennatas, E. D., Kramer, J. H., Miller, B. L. & Seeley, W. W. Predicting
667		regional neurodegeneration from the healthy brain functional connectome. Neuron 73,
668		1216-1227 (2012).
669	23	Raj, A., Kuceyeski, A. & Weiner, M. A network diffusion model of disease
670		progression in dementia. Neuron 73, 1204-1215, doi:10.1016/j.neuron.2011.12.040
671		(2012).
672	24	Shafiei, G. et al. Network structure and transcriptomic vulnerability shape atrophy in
673		frontotemporal dementia. Brain, doi:10.1093/brain/awac069 (2022).
674	25	Di Biase, M. A. et al. Linking Cortical and Connectional Pathology in Schizophrenia.
675		Schizophr Bull 45, 911-923, doi:10.1093/schbul/sby121 (2019).
676	26	Wannan, C. M. J. et al. Evidence for Network-Based Cortical Thickness Reductions
677		in Schizophrenia. American Journal of Psychiatry, appi.ajp.2019.18040380,
678		doi:10.1176/appi.ajp.2019.18040380 (2019).
679	27	Cauda, F. et al. The morphometric co-atrophy networking of schizophrenia, autistic
680		and obsessive spectrum disorders. <i>Hum Brain Mapp</i> 39 , 1898-1928,
681		doi:10.1002/hbm.23952 (2018).
682	28	Jiang, Y. <i>et al.</i> Antipsychotics effects on network-level reconfiguration of cortical
683	-0	morphometry in first-episode schizophrenia. <i>medRxiv</i> , 2021.2001.2017.21249965,
684		doi:10.1101/2021.01.17.21249965 (2021).
685	29	Hettwer, M. <i>et al.</i> Coordinated cortical thickness alterations across six
686	2)	neurodevelopmental and psychiatric disorders. <i>Nature Communications</i> 13 , 1-14
687		(2022).
688	30	Cauda, F. <i>et al.</i> Brain structural alterations are distributed following functional,
689	50	anatomic and genetic connectivity. <i>Brain</i> 141, 3211-3232 (2018).
690	31	Shafiei, G. <i>et al.</i> Spatial patterning of tissue volume loss in schizophrenia reflects
690 691	51	brain network architecture. <i>Biological psychiatry</i> 87 , 727-735 (2020).
692	32	Chopra, S. <i>et al.</i> Functional connectivity in antipsychotic-treated and antipsychotic-
692 693	52	naive patients with first-episode psychosis and low risk of self-harm or aggression: a
693 694		secondary analysis of a randomized clinical trial. <i>JAMA psychiatry</i> 78 , 994-1004
694 695		
093		(2021).

(0)(22	
696	33	Francey, S. M. <i>et al.</i> Psychosocial Intervention With or Without Antipsychotic
697 698		Medication for First-Episode Psychosis: A Randomized Noninferiority Clinical Trial. <i>Schizophrenia Bulletin Open</i> 1 , doi:10.1093/schizbullopen/sgaa015 (2020).
698 699	34	Lewandowski, K. E., Bouix, S., Ongur, D. & Shenton, M. E. Neuroprogression across
700	54	the early course of psychosis. <i>Journal of psychiatry and brain science</i> 5 (2020).
700	35	Bustillo, J. R. <i>et al.</i> Glutamatergic and neuronal dysfunction in gray and white matter:
701	35	a spectroscopic imaging study in a large schizophrenia sample. <i>Schizophrenia bulletin</i>
702		43 , 611-619 (2017).
703	36	Çetin, M. S. <i>et al.</i> Thalamus and posterior temporal lobe show greater inter-network
705	50	connectivity at rest and across sensory paradigms in schizophrenia. <i>Neuroimage</i> 97,
706		117-126, doi:10.1016/j.neuroimage.2014.04.009 (2014).
707	37	Esteban, O. <i>et al.</i> MRIQC: Advancing the automatic prediction of image quality in
708	57	MRI from unseen sites. <i>PLOS ONE</i> 12 , e0184661, doi:10.1371/journal.pone.0184661
709		(2017).
710	38	Gaser, C. & Dahnke, R. CAT - A Computational Anatomy Toolbox for the Analysis
711		of Structural MRI Data. <i>HBM</i> , 336-348 (2016).
712	39	Ashburner, J. et al. SPM12 manual. Wellcome Trust Centre for Neuroimaging,
713		London, UK 2464 (2014).
714	40	Schwarz, D. & Kašpárek, T. Comparison of Two Methods for Automatic Brain
715		Morphometry Analysis. Radioengineering 20 (2011).
716	41	Guillaume, B., Hua, X., Thompson, P. M., Waldorp, L. & Nichols, T. E. Fast and
717		accurate modelling of longitudinal and repeated measures neuroimaging data.
718		NeuroImage 94, 287-302, doi:10.1016/j.neuroimage.2014.03.029 (2014).
719	42	Schaefer, A. et al. Local-Global Parcellation of the Human Cerebral Cortex from
720		Intrinsic Functional Connectivity MRI. Cerebral Cortex (New York, N.Y.: 1991) 28,
721		3095-3114, doi:10.1093/cercor/bhx179 (2018).
722	43	Tian, Y., Margulies, D. S., Breakspear, M. & Zalesky, A. Topographic organization
723		of the human subcortex unveiled with functional connectivity gradients. Nature
724		Neuroscience 23, 1421-1432, doi:10.1038/s41593-020-00711-6 (2020).
725	44	Murphy, K. & Fox, M. D. Towards a consensus regarding global signal regression for
726		resting state functional connectivity MRI. <i>Neuroimage</i> 154 , 169-173,
727		doi:10.1016/j.neuroimage.2016.11.052 (2017).
728	45	Aquino, K. M., Fulcher, B. D., Parkes, L., Sabaroedin, K. & Fornito, A. Identifying
729		and removing widespread signal deflections from fMRI data: Rethinking the global
730	10	signal regression problem. <i>Neuroimage</i> 212 , 116614 (2020).
731	46	Betzel, R. F. & Bassett, D. S. Specificity and robustness of long-distance connections
732		in weighted, interareal connectomes. <i>Proceedings of the National Academy of</i>
733	47	Sciences, 201720186, doi:10.1073/PNAS.1720186115 (2018).
734 725	47	Raj, A., Kuceyeski, A. & Weiner, M. A network diffusion model of disease progression in dementia. <i>Neuron</i> 73 , 1204-1215, doi:10.1016/j.neuron.2011.12.040
735 736		(2012).
737	48	Raj, A. <i>et al.</i> Network diffusion model of progression predicts longitudinal patterns of
738	40	atrophy and metabolism in Alzheimer's disease. <i>Cell reports</i> 10 , 359-369 (2015).
739	49	Pandya, S. <i>et al.</i> Predictive model of spread of Parkinson's pathology using network
740	77	diffusion. <i>NeuroImage</i> 192 , 178-194 (2019).
741	50	Carletti, F. <i>et al.</i> Alterations in White Matter Evident Before the Onset of Psychosis.
742		Schizophrenia Bulletin 38 , 1170-1179, doi:10.1093/schbul/sbs053 (2012).
743	51	Di Biase, M. A. <i>et al.</i> White matter changes in psychosis risk relate to development
744		and are not impacted by the transition to psychosis. <i>Molecular Psychiatry</i> ,
745		doi:10.1038/s41380-021-01128-8 (2021).

746	52	Kraguljac, N. V. et al. White matter integrity, duration of untreated psychosis, and
747	52	antipsychotic treatment response in medication-naïve first-episode psychosis patients.
748		<i>Molecular Psychiatry</i> 26 , 5347-5356, doi:10.1038/s41380-020-0765-x (2021).
749	53	Kelly, S. <i>et al.</i> Widespread white matter microstructural differences in schizophrenia
750	55	across 4322 individuals: results from the ENIGMA Schizophrenia DTI Working
751		Group. <i>Molecular psychiatry</i> 23 , 1261-1269 (2018).
752	54	Bradshaw, N. J. & Korth, C. Protein misassembly and aggregation as potential
753	54	convergence points for non-genetic causes of chronic mental illness. <i>Molecular</i>
754		psychiatry 24, 936-951 (2019).
755	55	Guo, J. L. & Lee, V. M. Cell-to-cell transmission of pathogenic proteins in
756	55	neurodegenerative diseases. <i>Nature medicine</i> 20 , 130-138 (2014).
757	56	Yao, L. <i>et al.</i> White matter deficits in first episode schizophrenia: An activation
	50	
758		likelihood estimation meta-analysis. <i>Progress in Neuro-Psychopharmacology and</i>
759		<i>Biological Psychiatry</i> 45 , 100-106, doi: <u>https://doi.org/10.1016/j.pnpbp.2013.04.019</u>
760	<i>5</i> 7	
761	57	Arnatkeviciute, A. <i>et al.</i> Genetic influences on hub connectivity of the human
762		connectome. <i>Nature Communications</i> 12 , 4237, doi:10.1038/s41467-021-24306-2
763	5 0	
764	58	Fornito, A., Arnatkevičiūtė, A. & Fulcher, B. D. Bridging the Gap between Null _{rewire}
765		and Transcriptome. <i>Trends Cogn Sci</i> 23, 34-50, doi:10.1016/j.tics.2018.10.005
766	-0	(2019).
767	59	Hansen, J. Y. et al. Mapping neurotransmitter systems to the structural and functional
768		organization of the human neocortex. <i>bioRxiv</i> , 2021.2010.2028.466336,
769	60	doi:10.1101/2021.10.28.466336 (2022).
770	60	Hansen, J. Y. et al. Local molecular and global connectomic contributions to cross-
771		disorder cortical abnormalities. Nature communications 13, 1-17 (2022).
772	61	Lipska, B. K. & Weinberger, D. R. A neurodevelopmental model of schizophrenia:
773		neonatal disconnection of the hippocampus. Neurotoxicity research 4, 469-475
774		(2002).
775	62	Rosso, I. M. et al. Obstetric risk factors for early-onset schizophrenia in a Finnish
776		birth cohort. American Journal of Psychiatry 157, 801-807 (2000).
777	63	Bearden, C. E., Meyer, S. E., Loewy, R. L., Niendam, T. A. & Cannon, T. D. The
778		neurodevelopmental model of schizophrenia: Updated. Developmental
779		Psychopathology: Volume Three: Risk, Disorder, and Adaptation, 542-569 (2015).
780	64	Osimo, E. F., Beck, K., Reis Marques, T. & Howes, O. D. Synaptic loss in
781		schizophrenia: a meta-analysis and systematic review of synaptic protein and mRNA
782		measures. Molecular Psychiatry 24, 549-561, doi:10.1038/s41380-018-0041-5
783		(2019).
784	65	Harrison, P. J. & Eastwood, S. L. Neuropathological studies of synaptic connectivity
785		in the hippocampal formation in schizophrenia. <i>Hippocampus</i> 11, 508-519 (2001).
786	66	Radhakrishnan, R. et al. In vivo evidence of lower synaptic vesicle density in
787		schizophrenia. Molecular Psychiatry, doi:10.1038/s41380-021-01184-0 (2021).
788	67	Onwordi, E. C. et al. Synaptic density marker SV2A is reduced in schizophrenia
789		patients and unaffected by antipsychotics in rats. Nature Communications 11, 246,
790		doi:10.1038/s41467-019-14122-0 (2020).
791	68	Weinberger, D. R. Implications of Normal Brain Development for the Pathogenesis of
792		Schizophrenia. Archives of General Psychiatry 44, 660-669,
793		doi:10.1001/archpsyc.1987.01800190080012 (1987).

794 795	69	Lodge, D. J. & Grace, A. A. Hippocampal dysregulation of dopamine system function and the pathophysiology of schizophrenia. <i>Trends in pharmacological sciences</i> 32 ,
796		507-513 (2011).
797	70	Grace, A. Dopamine system dysregulation by the hippocampus: implications for the
798	10	pathophysiology and treatment of schizophrenia. <i>Neuropharmacology</i> 62 , 1342-1348
799		(2012).
800	71	Modinos, G., Allen, P., Grace, A. A. & McGuire, P. Translating the MAM model of
801	/ 1	psychosis to humans. <i>Trends Neurosci</i> 38 , 129-138, doi:10.1016/j.tins.2014.12.005
802		(2015).
803	72	Sabaroedin, K., Tiego, J. & Fornito, A. Circuit-based approaches to understanding
804	12	corticostriatothalamic dysfunction across the psychosis continuum. <i>Biological</i>
805		Psychiatry (2022).
806	73	Lieberman, J. <i>et al.</i> Hippocampal dysfunction in the pathophysiology of
807	15	schizophrenia: a selective review and hypothesis for early detection and intervention.
808		Molecular psychiatry 23, 1764-1772 (2018).
809	74	Schobel, S. A. <i>et al.</i> Imaging patients with psychosis and a mouse model establishes a
810	, 1	spreading pattern of hippocampal dysfunction and implicates glutamate as a driver.
811		Neuron 78, 81-93 (2013).
812	75	Vidal, C. N. <i>et al.</i> Dynamically Spreading Frontal and Cingulate Deficits Mapped in
813	10	Adolescents With Schizophrenia. Archives of General Psychiatry 63, 25-34,
814		doi:10.1001/archpsyc.63.1.25 (2006).
815	76	Thompson, P. M. <i>et al.</i> Mapping adolescent brain change reveals dynamic wave of
816	, 0	accelerated gray matter loss in very early-onset schizophrenia. <i>Proceedings of the</i>
817		<i>National Academy of Sciences</i> 98 , 11650-11655, doi:10.1073/pnas.201243998 (2001).
818	77	Sun, D. et al. Progressive Brain Structural Changes Mapped as Psychosis Develops in
819		'At Risk' Individuals. Schizophrenia research 108, 85-92,
820		doi:10.1016/j.schres.2008.11.026 (2009).
821	78	Sun, D. et al. Brain surface contraction mapped in first-episode schizophrenia: a
822		longitudinal magnetic resonance imaging study. Molecular Psychiatry 14, 976-986,
823		doi:10.1038/mp.2008.34 (2009).
824	79	Jalbrzikowski, M. Association of Structural Magnetic Resonance Imaging Measures
825		With Psychosis Onset in Individuals at Clinical High Risk for Developing Psychosis:
826		An ENIGMA Working Group Mega-analysis. JAMA Psychiatry 78, 753-766,
827		doi:10.1001/jamapsychiatry.2021.0638 (2021).
828	80	Cannon, T. D. et al. Progressive reduction in cortical thickness as psychosis develops:
829		a multisite longitudinal neuroimaging study of youth at elevated clinical risk. Biol
830		Psychiatry 77, 147-157, doi:10.1016/j.biopsych.2014.05.023 (2015).
831	81	Chung, Y. et al. Cortical abnormalities in youth at clinical high-risk for psychosis:
832		Findings from the NAPLS2 cohort. NeuroImage: Clinical 23, 101862,
833		doi: <u>https://doi.org/10.1016/j.nicl.2019.101862</u> (2019).
834	82	Del Re, E. C. et al. Baseline Cortical Thickness Reductions in Clinical High Risk for
835		Psychosis: Brain Regions Associated with Conversion to Psychosis Versus Non-
836		Conversion as Assessed at One-Year Follow-Up in the Shanghai-At-Risk-for-
837		Psychosis (SHARP) Study. Schizophrenia Bulletin 47, 562-574 (2021).
838	83	Collins, M. A. et al. Accelerated cortical thinning precedes and predicts conversion to
839		psychosis: The NAPLS3 longitudinal study of youth at clinical high-risk. <i>Mol</i>
840	.	Psychiatry, doi:10.1038/s41380-022-01870-7 (2022).
841	84	Cropley, V. L. et al. Accelerated Gray and White Matter Deterioration With Age in
842		Schizophrenia. Am J Psychiatry 174, 286-295, doi:10.1176/appi.ajp.2016.16050610
843		(2017).

- 844 85 Gogtay, N., Vyas, N. S., Testa, R., Wood, S. J. & Pantelis, C. Age of onset of
 845 schizophrenia: perspectives from structural neuroimaging studies. *Schizophr Bull* 37,
 846 504-513, doi:10.1093/schbul/sbr030 (2011).
- 847 86 Wolfers, T. *et al.* Mapping the Heterogeneous Phenotype of Schizophrenia and 848 Bipolar Disorder Using Normative Models. *JAMA Psychiatry*,
- 849 doi:10.1001/jamapsychiatry.2018.2467 (2018).
- 850 87 Lv, J. *et al.* Individual deviations from normative models of brain structure in a large
 851 cross-sectional schizophrenia cohort. *Molecular Psychiatry* 26, 3512-3523,
 852 doi:10.1038/s41380-020-00882-5 (2021).
- 853 88 Segal, A. *et al.* Regional, circuit, and network heterogeneity of brain abnormalities in
 854 psychiatric disorders. *medRxiv*, 2022.2003.2007.22271986,
 855 doi:10.1101/2022.03.07.22271986 (2022).
- 856 89 Leucht, S. *et al.* Clinical implications of Brief Psychiatric Rating Scale scores. *British Journal of Psychiatry* 187, 366-371, doi:10.1192/bjp.187.4.366 (2005).
- Henry, L. P. *et al.* The EPPIC Follow-Up Study of First-Episode Psychosis: LongerTerm Clinical and Functional Outcome 7 Years After Index Admission. *The Journal of Clinical Psychiatry* **71**, 716-728, doi:10.4088/JCP.08m04846yel (2010).
- 861